Institutional Review Board (IRB) Guidebook

This guidebook includes all of the information previously found on the Institutional Review Board (IRB) webpage.

After clicking into a topic, navigation within the book or page can be found on the left side of your screen. Above the page lists your current location within the content structure. If needed you will find a search function at the top of the page which may also be used for fast navigation.

The FAQ page will assist in directing you to the appropriate section of the guidebook based on your question.

If you have any questions, please contact us at 402-559-6463 or by email at irbora@unmc.edu

Research Support System (RSS)

Introduction

irb-ars-building.png Mailing Address:

Institutional Review Board
University of Nebraska Medical Center
987830 Nebraska Medical Center
Omaha, NE 68198-7830
Phone: 402-559-6463 Email: irbora@unmc.edu

The Institutional Review Board (IRB) is a committee formally constituted under federal regulations and institutional policy, and charged with reviewing research involving human subjects to protect the rights and welfare of those subjects. The IRB is composed of members from a variety of scientific disciplines as well as persons from the community. The IRB has the authority to approve, require modifications in (to secure approval), or disapprove research. The IRB also serves as a resource for researchers by providing advice and guidance on ethical and regulatory issues related to human subject research.

The Office of Regulatory Affairs (ORA) is the administrative department that provides support for the functions of the IRB. The ORA also serves as a final gateway for research review by assuring that all other institutional committee reviews and approvals have been obtained, and that all institutional requirements have been met.

The IRB and the ORA are committed to facilitating the conduct of ethical research involving human subjects, in full compliance with federal, state and institutional requirements.

Please contact us at irbora@unmc.edu for assistance with the submission of all IRB Applications and forms.

The pages and chapters to the right of your screen will take you to relevant topics and areas of interest. If there is anything you would like to see added to this guidebook, please let us know.

If you are new to research and working with the IRB, please visit this page for an introduction to the regulatory process.

Information regarding IRB staff, chairs, IRB members, and the Assistant Vice Chancellor; as well as contact information can be found here.

IRB Office Hours

We can be reached by phone (402-559-6463) or by email (irbora@unmc.edu) Mon-Fri 7am-5pm.

The IRB offers two virtual learning/training sessions each month.

Please direct questions regarding virtual training hours to the IRB Education Coordinator: Megan Berger mberger@unmc.edu or 402-559-6044

IORG #0000392

UNMC IRB Federal Wide Assurance

IRB Number for Each IRB:

AAHRPP Logo SMARTirb Logo

IRB News & Updates

Congruency, Consent, and Recruitment Materials

Dec 13th, 2024

In order to assure that subject injury language in the consent forms matches that in contracts, UNeHealth or SPA will begin conducting congruency checks. The congruency check is an institutional requirement and is a requirement for accreditation of our Human Research Protection Program.

Research teams should ensure a copy of the consent form is either developed or uploaded in RSS. The Office of Regulatory Affairs will notify SPA/UNeHealth of the requirement for a congruency check. If a discrepancy is found, SPA/UNeHealth will reach out to study teams directly to correct the consent form. Research teams will need to revise the consent developed in RSS or upload a copy of the revised consent (if relying on an external IRB) to RSS.

Congruency checks apply to studies that are conducted at UNMC, Nebraska Medicine, and Children's Nebraska that are:

Congruency checks are NOT required for:

For studies relying on an external IRB for oversight (CIRB studies), the Office of Regulatory Affairs will be reviewing consent forms to verify the required UNMC local consent language has been appropriately inserted into the consent. The required language is available on the UNMC IRB website. This review will also look for any consent language required by the UNMC Conflict of Interest Committee, as applicable.

CIRB Recruitment Materials

For studies relying on an external IRB for oversight (CIRB studies), the Office of Regulatory Affairs will begin reviewing recruitment to verify the materials conform to UNMC HRPP policies 3.5 and 3.6 . For existing studies, any new recruitment materials should be submitted as a change request. For new studies, recruitment materials should be uploaded to RSS at the time of initial submission.

Fee Increase

July 31st, 2024

To align with other academic medical centers and universities, effective September 1, 2024, the Office of Regulatory Affairs and the IRB will increase the IRB review fees for the initial review of protocols where UNMC relies on a commercial IRB. This will apply only to protocols submitted on or after September 1, 2024.

All investigators involved in research projects relying on a commercial IRB should include the IRB review fee in their grant or contract budget. A funding account must be provided at the time of IRB submission.

If you have any questions, please contact the Office of Regulatory Affairs at irbora@unmc.edu.

Advarra Submissions

July 2nd, 2024

Effective immediately, UNMC site submissions to Advarra may begin as soon as a study has been assigned a UNMC IRB number in the RSS system. Previously, Advarra required an Acceptance letter from the Office of Regulatory Affairs in order for study teams to begin the submission process with Advarra. Study teams will be required to provide Advarra with a copy of the "New Protocol" email as documentation of having a UNMC IRB number.

Emergency Preparedness (EP/COOP)

May 16th, 2024

We would like to remind clinical researchers about our Emergency Preparedness & Continuity of Operations Plan (EP/COOP), which is designed to:

The plan is available here: https://guides.unmc.edu/books/hrpp-policies-and-procedures/page/emergency-preparedness-continuity-of-operations-plan-%28epcoop%29

IRB Office Hours

January 19th, 2024

Intended for questions regarding research projects, filling in an application, policies, regulations, etc.

Please direct questions regarding office hours to the IRB Education Coordinator, Megan Berger: mberger@unmc.edu or 402-559-6044

We would like to remind everyone that IRB staff are available for assistance outside of office hours. If you ever need help outside of the designated office hours, please do not hesitate to reach out to an analyst or our main email, IRBORA@unmc.edu. We are happy to assist you via email, phone call, or video conference call during normal work hours.

Additional information can be found on our Education page [here](insert link here).

August 17th, 2023

The Office of the Vice Chancellor for Research and Office of Regulatory Affairs want to inform human subjects researchers about a temporary policy change.

Why it Matters: Over the next couple of months, temporary onboarding and training demands for new IRBORA staff may lead to a delay in timelines for IRB review and other ORA processes. The VCR and ORA recognize the potential impacts this could have on studies and have implemented a temporary policy change to lessen their effect and provide another option for studies.

What’s New: This policy change is currently in effect and provides an option for certain study teams to use Advarra or WCG as a Central IRB (cIRB).

What to Do: Investigator teams seeking to use one of these commercial IRBs as the IRB of record are required to submit a CIRB application to the UNMC IRB in addition to the application required by the commercial IRB.

Note: Studies should be aware of the following costs associated with using an external IRB: A one-time, $1,500 fee for UNMC review of CIRB studies to ensure compliance with local institutional guidelines. Any additional fees charged by external IRBs for review and use of their services

As a reminder: any human subjects research, whether reviewed by the UNMC IRB or by an external IRB, must adhere to all UNMC HRPP Policies, and must have the approval of all other relevant institutional committees.

For more information, visit the UNMC CIRB website or contact IRBORA@unmc.edu with any questions.

Bruce Gordon, MD Assistant Vice Chancellor for Regulatory Affairs Executive Chair, UNMC IRBs

Russell J. McCulloh, MD Associate Vice Chancellor for Clinical Research Institutional Official, UNMC IRBs

UNMC expanding support for ClinicalTrials.gov registrations

June 30th, 2023

The UNMC Office of the Vice Chancellor for Research and the Office of Regulatory Affairs are updating and expanding support for UNMC’s investigator-initiated studies registered on ClinicalTrials.gov.

To assist UNMC investigators in meeting the complex registration and reporting requirements in ClinicalTrials.gov, the two offices are rolling out an enhanced record monitoring and communication plans that will take effect on July 1.

Key enhancements include:

Over the next few months, additional support and resources will be provided through UNMC’s ORA, including expanded ClinicalTrials.gov information on the UNMC IRB website, a new decision-making tool for determining registration requirements and timing and more robust processes for record management and closure.

The goal is to bring studies registered on ClinicalTrials.gov through UNMC into full compliance with federal regulations, while reducing the complexity and burden of this process on investigators.

The National Institutes of Health and U.S. Food and Drug Administration have increased their enforcement efforts against reports of registration and reporting failures. Penalties can include substantial monetary fines and the suspension of funding for an investigator or the institution.

However, by collaborating with UNMC’s ORA and following the updated process, UNMC and its investigators can achieve full compliance and avoid these consequences.

ClinicalTrials.gov, launched in 2000, serves as a publicly accessible registry for clinical trials. The database provides the public with clinical trial information, while offering researchers access to valuable study data, promoting transparency and informed decision-making in clinical research.

Please email the Office of Regulatory Affairs for more information irbora@unmc.edu.

cIRB webpage update

March 6th, 2023

The cIRB page of the IRB website has recently been reworked. Please feel free to visit the page for updated information as well as a list of helpful forms and links. Keep an eye out for upcoming changes to the sIRB information available on the website!

If you have any questions, please email sirb@unmc.edu or call 402-559-6463.

Reminder regarding Protocol Approval Expiration

January 17, 2023

Investigators and research teams are reminded that annual continuing review is required for research originally approved by the convened IRB (protocols designated FB) as well as most research approved before 2019. As always, reminders will be sent to the PI and the Lead Coordinator and/or Regulatory Contact 60 days and 45 days prior to approval expiration.

If Continuing Review is not submitted and re-approved by the IRB by the expiration date all human subject research activities must stop. This includes new subject accrual, as well as follow-up of existing subjects and data analysis.

If continuation of research activities is in the best MEDICAL interest of already enrolled subjects (that is, the research presents the potential for direct benefit to subjects) you may submit the “Request to Continue Treatment for Enrolled Subjects on Approval Expired Studies" form, available in RSS.

If a Continuing Review application is not submitted within 30 calendar days, the study will be closed, and re-activation of a closed protocol will require submission of a new IRB application.

If all study activities, including all follow-up and data analysis, are completed, and all ClinicalTrials.gov reporting requirements have been met, you must submit a Study Completion Report, available in RSS.

Research which qualifies for Expedited Review (protocols designated EP) and some FB research that is in data analysis or clinical follow-up may not require annual continuing review. The initial approval letter, or a subsequent communication from the Office of Regulatory Affairs, will notify you if CR is not required.

If your research does not require annual CR you must still complete an annual Demographics form. If this form is not submitted within 20 days the protocol will be closed as above.

If you require assistance, please contact us at IRBORA@unmc.edu, or at 402-559-6463

August 26, 2022

Investigators are reminded that obtaining blood samples or other biological specimens for research, whether from a patient or from an employee or other normal volunteer, for use now or in the future, requires IRB approval and written informed consent. This includes drawing blood as “controls” for in vitro assays, unless those assays are performed solely for clinical purposes (and usually in a CLIA certified laboratory).

The IRB is happy to work with you to develop protocols to encompass a number of different activities involving collection of samples from human subjects, and to discuss further. Please contact us at IRBORA@unmc.edu, or at 402-559-6463.

Conducting human subject research without IRB approval and informed consent, including obtaining blood or other biospecimens for any research purpose, is serious non-compliance and may be reported to HHS, FDA, NIH, or other Federal authorities."

cIRB Application Update

June 24, 2022

1 - The CIRB application has been updated to include a contact information sheet which can be automatically generated in RSS. This contact sheet includes the Rights of Research Subjects and Research Questions

2 - Additional questions have been added to the CIRB application:

Financial Interest Disclosure

June 21, 2022

As of June 21, 2022, PIs and Faculty Advisors must personally complete the Financial Interest Disclosure questions at the time they are signing section I of the application. Though other research personnel may collaborate on completing other sections of the IRB application, no one other than the individuals signing the application will have the ability to answer the financial disclosure questions. This change applies not only to new applications but also to approved applications when a change request is initiated.

Revised Paper Continuing Review Forms

June 17, 2022

The continuing review applications for existing paper applications have been revised. These forms have been revised to remove personnel changes from the continuing review so that the continuing review and personnel changes on paper applications are handled like the electronic applications in RSS. These forms can be found on the IRB website: https://www.unmc.edu/irb/procedures/forms/paper-protocols.html

RSS New Application Update

June 8, 2022

All IRB applications begun after today will no longer require certification and signature by a Resource Reviewer.

Investigators are reminded that they are still responsible for assuring that there are adequate resources available to conduct the research, and to protect the rights and welfare of human subjects.

COVID-19 Update

February 9, 2022

The request to voluntarily defer the start of new protocols and pause face-to-face research activities is now lifted. Investigators should continue to use remote visits, when and where feasible, and review all subjects for potential exposures or risk before any scheduled face-to-face visit. Location or timing of visits may still be impacted by changes in Nebraska Medicine or other clinical facility changes and/or staff shortages.

Reinforcing COVID-19 Guidelines

January 11, 2022

With increasing cases of COVID and COVID breakthrough, we want to clarify/reinforce the new UNMC/Nebraska medicine policies as they are relevant to research spaces. We will make one change in our current policy regarding volunteers in research labs.

For all research programs:

For all lab building and lab-based programs:

All volunteers must be vaccinated, no exceptions or exemptions, and show evidence of vaccination, per our policy. They should be strongly encouraged to obtain a booster, as soon as they are eligible.

For all face to face clinical research programs:

Continue to follow your approved biosafety protocol, and all policies of the institution where the research is to be conducted regarding masking, which may now require providing surgical/procedural masks for subjects or accompanying persons.

Demographic Data Requirement Update

January 10, 2022

The Vice Chancellor of Research and the IRB now require that all human research studies provide demographic data (gender, race, and ethnicity) of all enrolled subjects, at time of annual review. This information will be submitted as part of the Continuing Review form, for studies requiring continuing review. For studies not requiring Continuing Review, PIs and Lead Coordinators will receive an email directing him/her to a new Demographics form which has been generated in the FORMS section of your application in RSS.

DocuSign Availability for Electronic Signature

December 6, 2021

DocuSign may now be available for use to document research informed consent in the limited cases where sponsors require its use. This is limited to research NOT subject to the FDA regulations. There may be a charge associated with use of DocuSign; contact Courtney Kennedy in IT for approval or for more information. In addition to DocuSign, investigators may continue to use the RSS e-signature system as previously noted.

Electronic Signature through RSS Expanded Availability

November 11, 2021

Previously only available for studies that were not Federally funded, the RSS e-signature function may now be used for Federally funded research studies also. To request use of this function, please send a message to the IRB via the RSS message portal. Please note, the RSS e-signature function is NOT available for any study that is FDA regulated regardless of funding source.

1 - What is remote consent?

2 - What is e-Signature?

3 - What is the difference between remote consent and e-signature?

4 - What platforms are allowed for e-signature?

5 - How do I access these systems?

Changes in the IRB Application

June 10, 2021

Which applications are affected?

Biomedical and Soc/Beh, Human Biologic Material, Medical Records research, Tissue Bank, Data Registry and Humanitarian Use Device protocols.

What are the changes?

When do these changes take place?

I just started a new application last week and have not yet submitted it, do I need to start another new application?

If you have any concerns please contact us by phone 402-559-6463 or email irbora@unmc.edu

IRB Commercial/Industry Fee Changes

March 17, 2021

In line with most other academic medical centers and universities, effective July 1, 2021, the Office of Regulatory Affairs and the IRB will begin charging an annual fee for continuing review of commercial/industry sponsored protocols. This will apply only to protocols submitted after July 1, 2021. In addition, fees for expedited review, and for protocols where UNMC relies on a commercial IRB (like Advarra or WIRB) will increase.

A WBS number must be provided at the time of IRB submission, and billing will occur at the time of IRB review. The protocol will not be released until review fees are paid. Therefore, all investigators involved in commercially sponsored research projects should include the IRB review costs in their grant or contract budget.

If you have any questions regarding this policy, please contact Bruce Gordon, MD

Christopher J. Kratochvil, M.D. Executive Director, Global Center for Health Security Associate Vice Chancellor for Clinical Research, UNMC Vice President for Research, Nebraska Medicine Chief Medical Officer, UNeHealth

Bruce Gordon, MD Assistant Vice-Chancellor for Regulatory Affairs Executive Chairman, Institutional Review Boards Institutional Official, Institutional Biosafety Committee Professor, Pediatrics University of Nebraska Medical Center 987680 Nebraska Medical Center Omaha, NE 68198-7680 bgordon@unmc.edu

Frequently Asked Questions (FAQ)

Below are a number of commonly asked questions. The questions will either provide an answer or will link to the appropriate section of the guidebook. The Page Navigation found in the upper left side of the page can be used to scroll directly to the answer needed and are organized by question. If you do not see your questions listed below, the Book Navigation on the lower left side of the page can be used to browse the various sections. The search bar at the top of the page may also help you navigate to the appropriate section.

Feel free to contact us at irbora@unmc.edu if you cannot find the needed content.

Do I need IRB review?

What application should I use?

What does Exempt mean?

Exempt does not mean exempt from an ethics review, but rather exempt from the federal regulations. Research is exempt from the federal regulations only if it falls under one of the specific exemption categories laid out in 45 CFR 46.

Exempt research protocols - Can I make a Request for Change?

Changes are typically not required for exempt (EX) projects. Changes are only required if an individual being added to the protocol needs access to it in RSS, a new Principal Investigator is being added, or if there is a change to the level of risk that moves the project out of the Exempt category at which point you would need to put through a new application. This is outlined in your approval letter. If more information is needed, please contact your protocol analyst or the IRB by using the RSS message portal for your Exempt protocol.

Is my research project expedited or full board?

The determination of whether a project will be considered Expedited or Full Board will be made by the IRB analyst during the review of the application. If you have a application deadline that requires an expedient review, this can be notated in the IRB application itself in Section 1.4: expedite.png

How long does it take for my research project to get approved?

There are many factors involved in IRB review depending on the complexity of the application and how many departments in the Office of Regulatory Affairs must be involved. On average an application will be reviewed between 7 and 28 working days. study_approval_irb_vs_ora.png

I have a CITI question.

I have an RSS question.

My protocol closes soon, what do I do?

Any protocol which needs to be renewed for another year will fall under one of two scenarios: Continuing Review (Full Board or greater than minimal risk studies) or a Demographic Recruiting Numbers form (EX, EP, CB, and minimal risk). Each will have their own respective form to be completed.

How do I complete a Continuing Review?

Instructions will be coming soon.

Do I need data from other sites on my Continuing Review (CR)?

How do I know my Accrual Numbers?

New study applications - when providing information for how many participants are going to be recruited, please provide a solid number value. Avoid using phrases like "approximately" or "around". It is acceptable to provide a larger number than anticipated as investigators can always accrue less participants than applied for, but going above the stated accrual numbers requires submission of a Request for Change and IRB review of stated change. Please take into account that screen failures and withdrawls count as accrual.

Continuing Review/Study Closure/Demographic Recruiting Numbers form - during the yearly renewal (or closure) phase of an investigator's protocol, demographics are often required as part of the process. If demographics are recorded as part of your project, it is advisable to document this information as participants are recruited making this information readily available when reporting is necessary.

How do I close my study?

What do I do if I have a problem?

How often does the IRB meet?

The IRB Boards meet once per month.

How do I delete a document or consent form?

Once a document or consent form has been deleted, it will be irretrievable. To avoid any accidental deletion of these documents, the request must be performed by a member of the IRB team. Please contact us through the RSS Message portal or at irbora@unmc.edu if this needs to be done.

How do I make a Change Request?

How do I reset my application to edit?

When going into the protocol in RSS, the Reset Edit button should be available at the top of the protocol page. If this does not appear, contact irbora@unmc.edu and the IRB can change the status. reset-edit.png

I'm a student, who needs to be listed on my protocol?

The student must be listed as the PI of the project, while the student's faculty advisor must be listed as both Secondary Investigator and Faculty Advisor. The Faculty Advisor role in RSS will appear when question 2.G in the application is answered "Yes".

How do I edit a consent form?

I'm leaving UNMC, what do I do with my research before I leave?

I have a cIRB/sIRB question.

My project was closed, what do I do?

Please contact irbora@unmc.edu with the protocol number. The circumstances of when and why a protocol was closed will depend on if and how the protocol can be reopened.

How does ClinicalTrials.gov work?

How do I compensate my participants?

I'm trying to add someone to my study in RSS, but I don't see their name.

All UNMC personnel will automatically receive an RSS profile with the creation of their institutional email address. If new employees do not appear in RSS within 48 hours of the creation of their email, please contact irbora@unmc.edu

If personnel do not appear who are members of local institutions (UNO, UNL, and Creighton), when going to https://net.unmc.edu/rss/ have them choose the appropriate institutional portal. This will redirect them to login with their institutional credentials and will sync their access with UNMC's RSS system.

For external institutions, please contact irbora@unmc.edu to determine the best course.

For instructions on how to add or delete personnel in RSS:

What do I need to report with an Incident Report?

How do I know if I need a Data Use Agreement?

When investigators are planning to share or receive data, two things must be considered:

  1. Is this Research – as determined by the IRB? and
  2. Does the data include Protected Health Information as defined under HIPAA?

If both of those answers are “yes” it will be necessary to proceed to a DUA.

If it is not research, but rather Quality Improvement (as determined by the IRB) and PHI is being shared, then the Privacy Office will be engaged to determine if a DUA is needed.

If de-identified data is being shared, the IRB does not require a DUA, however one still may be issued if 1) the investigator would like one in place to govern how the data is managed and/or 2) the other institution requires one to be in place.

HRPP (Human Research Policy & Procedures) Manual

The purpose of this policy and procedure is to provide a basic description of UNMC’s Human Research Protection Program (HRPP) through: 1) the Organization’s stated mission, 2) application of ethical principles to guide all human subject research under the oversight of the Organization, and 3) regulatory compliance with all applicable federal, state and local laws.

It is the policy of UNMC that the HRPP will: 1) ensure the rights and welfare of human subjects are protected, 2) evaluate and continually improve the protection of human research subjects, and 3) foster important human subject research in accordance with its mission.

Policies and Procedures Manual (searchable website)

Does my project require IRB review?

To help you determine if your project constitutes Human Subject Research and requires IRB review, you may complete the determination questionnaire by login into RSS.

RSS

The survey can be found in the IRB menu at the top of the page listed under the Application section.

doing_research.png

Click the "Am I Doing Research?" button as seen below. This will create a pop-up screen that will provide the survey you are familiar with. If the pop-up does not appear, you should see a notification at the top of your browser asking if you would like to allow RSS to generate the survey. All surveys taken by the user will be saved for later access. These can be accessed by clicking on the title of the project where indicated below.

doing_research2.png

This will allow you to access your determination survey at any time in the event that it is needed.

You may also consult the OHRP Decision Flow Charts to help you in making a determination.

Contact our office if you require further information at 402-559-6463 or irbora@unmc.edu.

Which application do I use?

There are eight applications to choose from depending on the type of research that is planned. Please make sure that you select the correct application type for your research. Once started, responses from one application cannot be transferred directly to a different application. Should you have any questions or are unsure as to which option to select, please contact the Office of Regulatory Affairs at 402-559-6463 or irbora@unmc.edu.

Biomedical or Social/Behavioral Research application:

Biomedical Research includes all human subject research performed with intent to develop or contribute to generalizable knowledge (i.e., test a hypothesis and draw conclusions) about human biological systems and processes, including efficacy and safety of preventative, diagnostic or therapeutic methods.

Behavioral and social science research includes all research performed with intent to study behaviors, attitudes and interactions and social processes among and between individuals, groups, and cultures. Generally this category of research has no intent of producing a diagnostic, preventive, or therapeutic benefit to the subject who is not seeking nor expecting a health benefit from the research.

Note: This research will subsequently be divided into therapeutic or non-therapeutic research. Therapeutic research is characterized as research which involves a drug, medical device, technique or other intervention or strategy (including means like diet, cognitive therapy, behavioral therapy, exercise) intended to diagnose, treat or prevent a particular condition or disease.

Human Biological Material (HBM) application:

Research involving the collection of human biological material (HBM) for use for this specific research project, or use of existing HBM (for example, from a biorepository) for a specific research project, or both, with no other type of physical interventions.

Note: HBM studies as described above which would additionally include the collection of medical information via surveys or by chart review should also be submitted using this application. If the sole purpose of this project is to obtain IRB approval for establishment of a tissue bank, complete the Tissue Banking Application.

Tissue Bank application:

Collection of human biological material (HBM) with no other type of physical or laboratory testing for the sole purpose of using the samples for FUTURE research.

Note: If the intent of the protocol is to collect HBM for use for this specific research with storage of left-over material after completion of this specific research, use the Human Biological Material (HBM) application.

Medical Records application:

Research involving the collection of information from medical records whether or not the information already exists or will be recorded in the future.

Note: Medical records research should not be submitted using the Exempt Application.

Data Registry application:

The collection of information/data (typically from medical records) for the sole purpose of using the data for FUTURE research.

Exempt Research application:

This application is only use for research which falls into specifically defined categories under the federal regulations (as outlined below). DO NOT use this application for medical record research.

  1. Research conducted in established or commonly accepted educational settings that specifically involves normal educational practices.
  2. Research that only involves educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior (including visual or auditory recording).
  3. Research involving benign behavioral interventions in conjunction with the collection of information from an adult subject through verbal or written responses.
  4. Research uses of identifiable private information (either publicly available or subsequently de-identified) that has been collected for some other activity.
  5. Research and demonstration projects that are conducted or supported by a Federal department and are designed to study, evaluate, improve, or otherwise examine public benefit or service programs.
  6. Taste and food quality evaluation and consumer acceptance studies.

Note: The Office of Regulatory Affairs (ORA) and the IRB have sole authority to determine whether a research project satisfies requirements for exemption. Contact the IRB Office if you have any questions - [irbora@unmc.edu](mailto:irbora@unmc.edu).

Humanitarian Use Device (HUD) application:

Use of a Humanitarian Use Device (HUD) which is a device that is intended to benefit patients in the treatment and diagnosis of diseases or conditions that affect fewer than 8,000 individuals in the United States per year.

Note: This application should not be used if the HUD is the subject of a clinical investigation in which safety and effectiveness data is being collected to support a pre-marketing approval (PMA) application. The IRB Application for Biomedical Research should be used instead.

Central IRB (cIRB)/Single IRB (sIRB) application:

Multisite research where UNMC will be relying on another IRB for review. This includes commercial IRBs like Advarra and CG-WIRB, Consortium or other Network IRBs, NIH or federal agency IRBs like the NCI CIRB, or other academic institutions. Click here for more information regarding cIRB and sIRB protocols or email sirb@unmc.edu.

Submission deadlines

IRB Submission Deadlines for New Submissions, Previously Tabled Protocols and Requests for Change

Adult Full Board Meetings

Adult Full Board Submission Deadline – 9 am

Submission Deadline Date of Adult Meeting
2/7/2025 2/20/2025
2/21/2025 3/6/2025
3/7/2025 3/20/2025
3/21/2025 4/3/2025
4/4/2025 4/17/2025
4/18/2025 5/1/2025
5/2/2025 5/15/2025
5/23/2025 6/5/2025
6/6/2025 6/19/2025
7/3/2025 7/17/2025
7/25/2025 8/7/2025
8/8/2025 8/21/2025
8/22/2025 9/4/2025
9/5/2025 9/18/2025
9/19/2025 10/2/2025
10/3/2025 10/16/2025
10/24/2025 11/6/2025
11/7/2025 11/20/2025
11/21/2025 12/4/2025
12/5/2025 12/18/2025
12/31/2025 1/15/2026

PEDs Full Board Meetings

PEDs Full Board Submission Deadline – 9 am

Submission Deadline Date of PEDs Meeting
2/13/2025 2/25/2025
3/13/2025 3/25/2025
4/10/2025 4/22/2025
5/15/2025 5/27/2025
6/12/2025 6/24/2025
7/10/2025 7/22/2025
8/14/2025 8/26/2025
9/11/2025 9/23/2025
10/16/2025 10/28/2025
11/13/2025 11/25/2025
12/4/2025 12/16/2025
1/15/2026 1/27/2026

sIRB Full Board Meetings

sIRB Full Board Submission Deadline – 9 am

Submission Deadline Date of sIRB Meeting
2/6/2025 2/14/2025
3/6/2025 3/14/2025
4/3/2025 4/11/2025
5/1/2025 5/9/2025
6/5/2025 6/13/2025
7/3/2025 7/11/2025
7/31/2025 8/8/2025
9/4/2025 9/12/2025
10/2/2025 10/10/2025
11/6/2025 11/14/2025
12/4/2025 12/12/2025
12/31/2025 1/9/2026

Report a research problem or complaint

Report a problem

Report a problem securely and confidentially through the UNMC Human Subjects Research Comment Portal.

Are you a research subject, staff or investigator who wants to report a complaint or problem to the IRB? By following the comment portal link, you will be directed to a REDCap form where you can enter information about your complaint that will be delivered to the IRB and to the UNMC Chief Compliance Officer. Reports can be made either anonymously or with contact information if you would like to be contacted about your concern.

Alternately, problems can be reported through University of Nebraska EthicsPoint.

By following the EthicsPoint link, you will be directed to a site where you can enter information about your complaint that will be delivered to the UNMC Chief Compliance Officer and University of Nebraska Central Administration.

Research Subjects

The types of complaints/problems that may be reported via this system include:

  1. Complaints or concerns regarding the conduct (e.g., health or safety concerns) of a research study that you are participating in currently or previously.
  2. Complaints or concerns regarding the research personnel conducting the study.

Research Staff and Investigators

The types of complaints/problems that may be reported via this system include:

  1. Complaints or concerns regarding the conduct of other researchers or staff members involved in a particular protocol.
  2. Complaints or concerns regarding IRB review of protocols or IRB policies and procedures.

IRB Assessment

If you would like to evaluate the IRB or provide feedback on how we have performed, please complete the following form. The form can be sent to the IRB at zip 7830 or sent by e-mail to irbora@unmc.edu.

Procedures

The IRB is committed to making the submission process as smooth as possible. In this section, you will find definitions, explanations and procedures for submitting an application and any other form that may be required during the course of a study.

If you have any questions, please contact us at irbora@unmc.edu

Procedures

Adverse Event Reporting

Adverse Events (AEs)

An Adverse Event is defined by the NIH as: Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research.

The IRB requires submission of an AE report form when the event is unexpected and related/possibly related to the research. Adverse events occurring on a study which satisfy these criteria must be submitted to the IRB within the timeline specified in the policy. Any death, which occurs while the subject is being treated on protocol or occurs within 30 days of completing research related interventions, must be reported immediately if it meets the reporting criteria.

For more information, please refer to HRPP policy 8.1

AEs will be submitted through the RSS system.

External Adverse Events

External Adverse Events are defined as: adverse events that occur at a site under external IRB oversight. External AEs are not reported to the IRB unless they require a change in protocol or revision of the consent document. These are not reported on an Adverse Event report form. The external AE report (i.e., IND Safety Report) is used as justification for the required changes.

External Adverse Device Effects (UADEs)

Unanticipated Adverse Device Effects (UADEs) are defined as: Unanticipated adverse device effect means any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

External AEs for device studies must be reported to the IRB (in no case no later than 5 business days following PI notification from the sponsor that the event occurred) in accordance the requirements of 21 CFR 812.150(b)(1).

The PI should submit the report received from the sponsor along with any required Request for Change.

Once the status of a study is changed to “completed,” the IRB will no longer accept external UADE reports except under circumstances where the report involves important new risk information.

For more information, please refer to HRPP policy 8.1

For any questions, please email irbora@unmc.edu

Procedures

ClinicalTrials.gov (CT.gov)

CT Logo

CT PRS Logo

Check back to this page for more updates regarding clinicaltrials.gov information.

Please contact oract.gov@unmc.edu for more information.

When requesting a new user account for ClinicalTrials.gov, please provide the following information:

Once the account is created, ClinicalTrials.gov will send an email with login information.

Note: For Student Principal Investigators, if your research study will be registered on ClinicalTrials.gov, please list your Faculty Advisor as the Responsible Party and yourself as Record Owner.

CITI Training Course for ClinicalTrials.gov

A new CITI training course is available to UNMC and UNO learners that provides video instructions for registering, uploading documents, and submitting results in ClinicalTrials.gov. Currently optional, the course is highly recommended as a guide to investigators new to ClinicalTrials.gov requirements and to experienced investigators needing a refresher.

When you have successfully completed the course, please email a copy of the Completion Certificate to oract.gov@unmc.edu.

ClinicalTrials.gov Icons in RSS

IRB protocols that are investigator-initiated and registered on ClinicalTrials.gov with an NCT# will now be denoted by an icon in RSS.

A green icon means no problems are currently identified by ClinicalTrials.gov on the record associated with the study.

ctgov__icon1.png

A red icon means ClinicalTrials.gov has identified problems on the associated record.

ctgov_icon2.png

If your study has a red icon, please login at https://register.clinicaltrials.gov to correct the problem(s). Icons are updated daily, Monday-Friday, so once problems are resolved, the icon will be green after the next daily update. If you have difficulty correcting a problem in https://register.clinicaltrials.gov, please contact oract.gov@unmc.edu for assistance.

Outstanding problems with the ClinicalTrials.gov record may delay the review and approval of IRB submissions. Please ensure all problem records are addressed as soon as possible (UNMC HRPP Policy 1.29).

Process for updating a record

Whenever a ClinicalTrials.gov record is updated, the process must be completed by approving and releasing the update.

Steps for completing an update of any type are displayed in the “Record Status” at the top of the record.

ctgov_icon3.png

The “Next Step” box is displayed immediately below which describes the next action needed.

Any problems with the update are listed in the “Next Step” box and may include:

Once the update problems are resolved, the next step is to click the “Entry Complete” button:

ctgov_icon4.png

The following step is to review the update, then click the “Approve” button:

ctgov_icon5.png

The last step is to click the “Release” button if you are the Responsible Party for the record:

ctgov_icon6.png

If you are the Record Owner, this “Next Step” box will be displayed, and the Responsible Party will need to login and release the update.

ctgov_icon7.png

When any problems with the update are resolved and the update has passed PRS review, the update is released to the public ClinicalTrials.gov site.

ctgov_icon8.png

All the steps on the “Record Status” will be highlighted in blue.

For any clinical trial conducted or supported by a federal agency or department or agency, Federal Regulations require the awardee of a grant to post one IRB approved informed consent form used to enroll subjects on a publicly available Federal Web site.

“Clinical trial” means a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

The PI must post:

The PI only needs to post ONE consent form used to enroll subjects anytime during the course of the study.

If your study is utilizes the Clinical Trials Monitoring System (CTMS) you will receive notification when your last subject is enrolled. The notification includes instructions about the requirement, and how to post to clinicaltrials.gov.

If your study does not utilize CTMS it is your responsibility to track subject enrollment, and post no later than 30 days after the last subject is enrolled.

Specific instructions on how to register with ClinicalTrials.gov and upload documents can be found here.

Procedures

Emergency Treatment

The contact list for Emergency Treatment authorization can be found here in RSS.

Under certain circumstances, a physician may treat a patient with an investigational (non-FDA approved) drug, biologic or device, or treat a patient utilizing a non-IRB approved protocol; Pursuant to FDA regulations, the patient must be suffering from a serious, life-threatening or debilitating illness for which there is no satisfactory treatment alternative(s) and there must not be sufficient time to obtain full IRB review and approval. Emergency treatment as defined here is not research. The FDA regulations do not provide for expedited IRB approval in emergency situations.

UNMC/Nebraska Medicine policy requires the IRB be notified prior to such use, by contacting the IRB office. This notification is not IRB approval. The IRB will only state it is aware of the proposed use and considers the use to meet the requirements of 21 CFR 56.102(d), 21 CFR 56.104(c), and the criteria in HRPP 6.4 Emergency Use of a Test Article, section 5.0 of the full policy.

The investigator is still required to obtain informed consent of the patient or the patient’s legally authorized representative. The consent form must contain appropriate elements structured to reflect that consent is for treatment purposes as opposed to research. View a sample Consent Form for Emergency Treatment

A useful guide can be found here: Emergency Use vs Expanded Access

The UNMC Emergency Use of a Test Article Report form can be found in RSS and a signed copy of the consent form must be submitted to the IRB within 5 business days following the treatment.

Procedures

Exempt Studies

It is understood this project will be conducted in full accordance with all applicable HRPP Policies. It is also understood that the ORA will be immediately notified of any proposed changes for your research project that:

  1. Affect the risk-benefit relationship of the research
  2. Pose new risks which are greater than minimal
  3. Constitute a new risk to privacy or confidentiality
  4. Involve sensitive topics (including but not limited to personal aspects of the subjects behavior, life experiences or attitudes)
  5. Involve deception
  6. Target a vulnerable population
  7. Include prisoners or children
  8. Otherwise suggest loss of the exempt status of the research.

No changes to exempt studies are required to be submitted for review, which is outlined in your approval letter. If you feel a change is warranted, please contact our office utilizing the message portal of the application in question.

You are encouraged to contact the ORA to discuss whether changes to exempt research requires review by the IRB or please view HRPP policy 2.6 (Exempt Research).

Procedures

Incidents (Non-compliance/Problems)

Per HRPP policy 8.4 non-compliance (NC) involving the PI and/or study personnel must be promptly reported to the IRB. This non-compliance could involve failure to comply with the Federal Regulations related to the protection of human subjects of research, HRPP policies, or the requirements/determinations of the IRB.

NC and problems are reported to the IRB by submission of an Incident Report Form. The Incident Report form is located in the Forms section of RSS. The PI is responsible for ensuring that the required reports are submitted promptly following discovery of the incident in accordance with HRPP policy 8.4.

If you have any questions regarding this submission process, please contact the IRB Office at irbora@unmc.edu

Procedures

Protocol Deviations

A Single Subject Protocol deviation is a change in an IRB-approved protocol which is permitted for an individual subject when it is in the best interest of that subject and/or is necessary for research purposes (e.g., data completion). Protocol deviations are classified as either “minor” or “more than minor.” Once the form is received, the deviation will be reviewed and processed by the IRB. Deviations may be approved in one of two ways:

  1. Deviations that are minor are eligible for expedited review under the provisions of HHS regulations at 45 CFR 46.110(b)(2) and FDA regulations at 21 CFR 56.110(b)(2), as applicable.
  2. Deviations that are more than minor do not qualify for expedited review and therefore must be reviewed by the full IRB.

Once the deviation is approved, an approval letter for the Single Subject Protocol Deviation will be attached to the electronic IRB application. The PI and Lead Coordinator will be notified via email when this occurs.

To obtain Single Subject Protocol Deviation approval, a Single Subject Protocol Deviation Request must be submitted PRIOR to the implementation of the deviation. The instructions for submission are below:

RSS Studies & Existing Paper Format Studies

The Single Subject Deviation form can be created by pulling up the protocol in RSS. The 'Forms' section will be found in the left-side menu. When clicking on 'Forms' a list will appear allowing you to choose the 'single subject protocol deviation request'. Please follow the instructions provided to complete the form and once competed the PI will electronically sign and click 'SUBMIT'.

If you have any questions regarding this submission process, please contact the IRB Office at irbora@unmc.edu.

Procedures

Submission Process

Full Board Review (initial submission)

Investigators will be notified of the assigned IRB# by email. Applications for Full Board Review will be reviewed at the next possible IRB meeting. Submission Deadlines can be found here.

These documents must also be attached in the "ADD DOCUMENTS" section of the online application at the time of electronic submission:

New Submissions (Initial)

  1. Subject Recruitment Material (as applicable)
  2. External study site approval letters (as applicable)
  3. Full protocol (as applicable)
  4. Investigator's Brochure (as applicable)
  5. Grant application (as applicable)
  6. Clinical Trial Master Matrix (as applicable)
  7. Other relevant material (e.g. surveys) (as applicable)

Tabled — Re-Submissions

  1. Investigator's response letter
  2. Other revised materials (as applicable)

Expedited Review (initial submission)

Certain studies involving no more than minimal risk may qualify for expedited review status under 45 CFR 46.110 or 21 CFR 56.110. View a list of categories which may qualify for expedited review.

Expedited review of new protocols are handled through the electronic submission only. New submissions eligible for expedited review will be reviewed by the IRB Analyst with appropriate confirmation by the Executive Chair/designee and the investigator will be informed of the IRB’s decision by email.

Exempt Protocols (initial submission)

Research activities in which the only involvement of human subjects will be in one or more of the categories specified by 45 CFR 46.101(b) are exempt from the requirements of 45 CFR 46. The exempt categories do not, however, apply to research involving deception of subjects, sensitive behavioral research, or to research involving pregnant women, prisoners, individuals who are decisionally impaired and other subject populations determined to be vulnerable.

Reviews of new Exempt protocols are handled through the electronic submission only. New Exempt submissions will be reviewed by a member of the Office of Regulatory Affairs (ORA) staff and the investigator will be informed of the ORA's decision by email.

Request for Change

Any proposed change in a research activity must be reviewed and approved by the IRB prior to implementation except when: 1) a change is necessary to eliminate an apparent immediate hazard to the subject(s), or 2) a subject needs to be advised immediately of significant new information. Administrative changes do not require IRB review and can, accordingly, be approved by ORA.

For studies submitted in electronic system, follow these steps:

For Studies NOT Submitted in Electronic System, follow these steps:

If you have any questions regarding this submission process, please contact the IRB Office.

Continuing Review Overview

Federal regulations require certain types of research undergo continuing review at least annually. Review and approval of continuing review must occur before the expiration date listed on the initial approval letter and, subsequent continuing review approval letters as the “valid until” date. Courtesy email reminder notifications are sent approximately two months before expiration and again two weeks later.

Federal regulations prohibit the IRB from granting extensions or temporary approval beyond the expiration date. Should expiration of IRB approval occur, all study related activities must cease as of the date of expiration.

A “Request to Continue Treatment for Enrolled Subjects on Approval Expired Studies” form must be submitted and approved to allow currently enrolled subjects to continue to receive study treatment. This form is available through the “Forms” link on study pages in RSS.

CR Electronic Submission

CR Existing Paper Protocol Submissions

Submission Deadlines

Studies requiring Full Board (convened IRB meeting) review, continuing review applications should be submitted 4-6 weeks before expiration.

Studies requiring expedited review, continuing review applications should be submitted four weeks prior to expiration, to allow time to address any required modifications.

Studies that do not require continuing review, are required to submit an annual update, which includes a report of subject demographics. Emails requesting the annual update are sent out the month the study will expire.

If you have any questions regarding this submission process, please contact the IRB Office at irbora@unmc.edu.

Education & Resources

The goal of the IRB Education Program is to facilitate research involving human subjects from initial submission to study completion through didactic and practical education. Whether it is for investigators, research study personnel, students or other institutional representatives, information is explained in a manner that fits the audience. By using a variety of delivery methods, such as lectures, webinars, live-streams, bulletins, one-on-one meetings and department in-service, from new student to seasoned investigator, our objective is to offer education of:

- The history and regulation of research ethics
- The local submission requirements and process
- The common pitfalls to improve the efficiency of the submission process.

The IRB is here to help!

All educational options will be tailored to meet the specific needs of the target audience, whether it be one-on-one about a specific research protocol or a lecture to a class regarding a general overview of research ethics and the IRB process.

If you would like to schedule a one-on-one meeting, department in-service, class lecture, Q&A session or any other type of IRB education, please contact IRB staff for assistance at irbora@unmc.edu

Education & Resources

HRPP Investigator Guidance Series

This page serves as a hub for all of the Investigator Guidance Series documents. Each document is an abbreviated version of one of our HRPP Policies and Procedures intended for investigators, coordinators, and other study team members. This page is a good starting point for any study team member with a question about a policy on a specific topic. A link to the full policy/procedure is included in each document.

Document Updated
Advertisements 12/13/2023
Authority of the IRB 12/13/2023
Change Requests 12/13/2023
cIRB 12/13/2023
Closure of Research 12/13/2023
Compensation 12/09/2024
Confidentiality 12/13/2023
Continuing Review 02/05/2024
Contraception Requirements 12/13/2023
Data and Safety Monitoring 12/13/2023
Data Registries 12/15/2023
Emergency Research - Waiving Consent 12/13/2023
Emergency Use of a Test Article 01/25/2024
Employees as Subjects 12/13/2023
Ethical Access 12/09/2024
Exempt Research 01/25/2024
Expanded Access to Investigational Drugs and Devices 12/14/2023
Expedited Review 12/13/2023
Financial COIs 01/25/2024
Full Board Review 12/13/2023
Humanitarian Use Device (HUD) 12/13/2023
Incidental Findings 12/13/2023
Increased monitoring, interim Continuing Review, and verification 12/15/2023
Informed Consent 12/13/2024
International Research 12/13/2023
Investigational and Marketed Devices 01/26/2024
Investigational and Marketed Drugs 12/13/2023
IRB Approval Criteria 12/15/2023
Obtaining Informed Consent for Non-English Speaking Persons 12/13/2023
Obtaining Informed Consent for Persons with Additional Needs 12/13/2023
PI Qualifications and Responsibilities (job description) 12/13/2023
Placebos 12/13/2023
Post-Approval Monitoring of Research 12/09/2024
Pregnancy Testing 12/13/2023
Privacy 01/26/2024
Recruitment 12/13/2023
Reimbursement 12/13/2023
Research Involving Children 12/13/2023
Research Involving Decisionally Impaired Persons 12/13/2023
Research Involving Neonates 12/13/2023
Research Involving Pregnant Women and Fetuses 12/13/2023
Research Involving Prisoners 01/25/2024
Research Personnel Qualifications & Responsibilities (study team job descriptions) 12/13/2023
Short Form Consent 12/13/2023
sIRB 12/13/2023
Students as Subjects 12/13/2023
Study Hold 12/13/2023
Suspension 12/13/2023
Termination 12/13/2023
Using PHI in Research 12/13/2023
Vulnerable Populations - Additional Protections 12/13/2023
Waiving Consent Process 12/13/2023
Waiving Signed Consent 12/13/2023
Wash Out 12/13/2023
What requires IRB review and approval? 01/10/2024
Education & Resources

Investigator Resources

Regulations:

National Institutes of Health:

UNMC Links:

Food and Drug Administration:

International Standards:

Other Federal Agencies:

Organizations and Other Items of Interest:

IRB History and Principles:

Education & Resources

Mental health considerations

MENTAL HEALTH CONSIDERATIONS FOR RESEARCHERS

DECEMBER 2023

EXPLANATION OF RISKS:

SELF-REPORT MEASURES:

INVESTIGATOR-ADMINISTERED MEASURES:

PHQ-9:

The Columbia Suicide Severity Rating Scale-Revised (CSSRS-R):

RESOURCES:

UNMC/NE MEDICINE PSYCHIATRY SERVICES:

PSYCHIATRY SERVICES FOR CHILDREN

PSYCHIATRY SERVICES FOR STUDENTS:

KEARNEY COMMUNITY RESOURCES

LINCOLN COMMUNITY RESOURCES

NORFOLK COMMUNITY RESOURCES

SCOTTSBLUFF COMMUNITY RESOURCES

NATIONAL RESOURCES

Education & Resources

Miscellaneous Resources

Below investigators will find a variety of resources that may assist with research goals:

Training

The topics found below will provide various learning resources for common IRB items.

If there is a topic that you would like to learn more about but do not see it listed below, please contact us at 402-559-6463 or at irbora@unmc.edu.

Training

CITI Training

citi_logo.png

What is CITI?

Collaborative Institutional Training Initiative (CITI) certification is an institutional requirement for all personnel engaging in Human Subject Research (HSR). It includes three primary modules that are required by the institution to participate in conducting various types of research: Group 1: Biomedical Research, Group 2: Good Clinical Practice (GCP), and Group 3: Social & Behavioral Research.

Faculty, employees, students and other institutional representatives at UNMC, Nebraska Medicine, CHMC, and UNO are required to complete the Human Subjects Research (HSR) course via CITI if they will be working on a research project that involves human subjects. It takes approximately 1-2 hours to complete a Basic course. The training does not have to be completed in one sitting, but can be spread out over time if needed.

Instructions

A PDF with instructions for how to navigate CITI can be found here.

Basic or Refresher?

The Basic course is designed to establish certification and should be taken when:

The Refresher course is designed to re-establish certification for three years and should be taken when:

Course required based on type of research:

Group 1: Biomedical Research – Investigators conducting research about human biological systems and processes, including efficacy and safety of preventative, diagnostic or therapeutic methods must take this course. Types of research:

Group 2: Good Clinical Practice (GCP) – Investigators conducting clinical trials funded by NIH, or utilizing an FDA regulated drug, device, or biologic must take this course. A clinical trial is defined as “a research study in which one or more human participants are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes”.

Investigators conducting these types of trials must also take the Biomedical course (Group 1).

This GCP course meets the minimum criteria for training identified by some sponsors. (Check to see if your sponsor is listed.) If so, your CITI completion report can be supplied to the sponsor to meet their GCP training requirement.

Group 3: Social & Behavioral – Investigators conducting research performed with intent to study:

Researchers/Students transferring from other institutions:

Please email all completion reports for previously completed CITI training courses to irbora@unmc.edu. CITI courses are unique from institution to institution and transcript comparison will be required. Only the completion report shows the modules required for transcript comparison. Once previous training has been updated, the IRB will determine if any additional training or Refresher courses will be required.

It is highly recommended that you email the Completion Report prior to beginning the Refresher course. Please do not send completion certificates.

Collaborators with UNMC:

Any independent entity collaborating with UNMC for the purposes of research must also complete CITI training as required by the institution. When registering for CITI, please affiliate with UNMC/UNO and do not register as an independent learner.

If you need assistance with your username and/or password from an institution other than UNMC/UNO, you can contact:

CITI Support: 888-529-5929 (9:00 a.m. to 7:00 p.m. EST/Monday – Friday).

If you have more than one CITI account, you can request that they be merged by calling CITI Support. Once merged, all training completed will be available under one account.

For all questions regarding CITI training, please contact the IRB Office at 402-559-6463 or email irbora@unmc.edu.

Training

Community Partners

All individuals that work on human subject research projects must complete human subject research training. Faculty, students, or employees of UNMC, NM, CHMC, UNO, BMC, or another academic partner institution are required to take CITI training. Community partners who collaborate on research projects may complete the CIRTification program as an alternative to the CITI Program.

Who are Community Partners?

Community partners are non-academic personnel (e.g. community leaders, representatives from supporting community organizations) engaged in research requiring IRB approval. This program is specifically and only for community members collaborating on human subject research studies.

Who is NOT considered a Community Partner?

Students or staff affiliated with UNMC, NM, CHMC, UNO, BMC, or research staff affiliated with other private entities directly engaging in human subject research.

What is CIRTification?

CIRTification is a training program in human research protections created by the University of Illinois Chicago CCTS that is tailored to the unique roles of community research partners. It is interactive and relevant to the roles and responsibilities that community partners have in research projects. The program considers community partners’ limited experience with research, discusses key concepts in research ethics and responsible conduct of research in plain language, and focuses on applying knowledge to real-life scenarios. Ideally, CIRTification Online will not only teach community partners about the importance of protecting research participants, it will also empower them to be active contributors to their respective research teams.

CIRTification introduces learners to the basics of the research - the terminology, people, and methods. It reviews the history of research abuses that have informed current ethical principles, rules, and regulations.

The training program also covers standard and best practices for:

What can I expect?

The program takes about 3-4 hours total to complete and can be completed in multiple sessions. The course is currently available in English, Spanish, and Haitian Creole. The course includes audio, video, text, and interactive activities.

Learners will complete a knowledge quiz at the end of the program and receive a date-stamped certificate of completion. Please save a copy of this certificate for your records and email a copy to IRBORA@unmc.edu.

Online Training Instructions:

Please follow the instructions below to enroll in CIRTification. Please select University of Nebraska Medical Center only from the list.

  1. Go to https://training.ccts.uic.edu/
  2. Click “Register” in the top right-hand corner.
  3. Select “I am not from UIC”.
  4. Complete the registration form. Under “Site”, select “University of Nebraska Medical Center”.
  5. Once the form is filled in, click “Register” at the bottom of the form.
  6. Visit the Course Catalog. Information about CIRTification will appear. Click “Learn More”.
  7. Click “Enroll” to start the CIRTification course.

Frequently Asked Questions (FAQ):

Who can I contact for help?
For assistance, place contact: Megan Berger at mberger@unmc.edu
How long is this training valid?
The training is valid for three years.
How do I access my completion certificate?
After completing the quiz at the end of the training, the option to print and save a date-stamped certificate of completion is available. If for some reason you missed this or are unable to complete this step, Megan Berger can access the completed training certificate. Email her at mberger@unmc.edu.

CIRTification is funded through the University of Illinois at Chicago Center for Clinical and Translational Science and supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. We encourage mention and citation of CIRTification Online in grant proposals, conference presentations, published manuscripts, and other reporting. Suggested citation: CIRTification Online: Community Involvement in Research Training. University of Illinois at Chicago, Center for Clinical and Translational Science.

Training

Consent Forms

Recent changes to the Federal Regulations governing human subject research (the “Common Rule”) have included a focus on improving the readability of consent forms and include regulations requiring understandable language, and organization and presentation of information that facilitates understanding.

In response to these requirements, beginning October 31, 2019, consent forms must satisfy minimum readability standards. We are working on a way to receive proof of PRISM training. Therefore, until further notice, we are not requiring physical proof, but written assurance.

Though we expect to extend the standard to other sections, initially only the readability of the Invitation and Summary section will be assessed.

This section must have Flesch Kincaid reading level ≤8 and Flesch Reading Ease ≥60. Readability may be scored within the RSS application by clicking on the “Readability” button.

CFs not meeting these minimum readability measures will be returned to the investigator for modification.

To assist investigators and their staff in developing necessary skills to write effective consent forms, the PI and the person responsible for writing the consent form, must complete online training through PRISM (Program for Readability in Science and Medicine). The hour-long training covers health literacy and readability, plain language strategies and examples, and interactive editing examples and exercises.

For more information on process, readability standards, and readability tips, see below.

Readability Assessment Process:

Readability Standards:

Tips for writing readable Consent Forms:

Do Do Not
Use short sentences and use words familiar to the non-medical reader. Use medical terminology without explaining it, or use words that an 8th grader would not understand.
Refer to thesauruses and medical glossaries made for children to find alternative ways to refer to medical terminology. Use medical “jargon” or words longer than three syllables, when another word is also appropriate.
Use the second person (“you”) and note that they are asked to participate in a research study. Be personal. Use the third person (“the subject”), and avoid writing “invite” to refer to their participation.
Use pictures and graphs wherever possible. Provide information solely in large blocks of text, with long sentences.
Say “for example” or “so forth.” Say e.g. or etc.
Use tablespoons or teaspoons to refer to the measurement of bodily fluids, and spell them out. Use ml or cc to refer to volumes of bodily fluids, or abbreviate teaspoons/tablespoons.
Say “greater than” or “less than”. Use “>” or “<” or other symbols that an 8th grader might have trouble understanding at first glance.
Describe study terminology such as “randomized”, “placebo”, or “double blind”; such as “like the flip of a coin”. Use medical or study terminology without explaining it in lay terms.
Use the words “study drug” or “study regimen”. Use the terms “therapy” or “treatment” to describe drugs, devices, or procedures.
Refer to investigational drugs or devices as “experimental” or “investigational”, and that it means the FDA has not yet approved it. Refer to investigational drugs or devices as “new.”

Readability Examples and Templates:

UNMC is recommending that study teams utilize the "teach-back" method during the informed consent process for their clinical studies. This method will enhance the informed consent process, ensuring participants are well-prepared before consenting and enrolling in clinical studies.

Our aim is to empower clinical research investigators and coordinators with the tools and knowledge to ensure that research study participants are fully informed and understand all aspects of the informed consent form.

Teach-Back Tool

Ethical Responsibility in Research

The Importance of Health Literacy

"Health literacy plays a crucial role in maintaining a healthy lifestyle and making informed decisions about our health care. Yet, a report from the HHS Surgeon General in 2019 highlighted that only 12% of Americans possess proficient health literacy skills. This underscores the importance of clear communication in the informed consent process."

Reference: HHS Surgeon General Reports and Publications, 2019

Consent Teach Back: A Strategy for Clarity

The 5 T’s of Teach Back

  1. Triage: Concentrate on one topic at a time.
  2. Tools: Utilize models, written tools, posters, graphics, etc., to aid in explaining the desired information.
  3. Take Responsibility: Phrase it as, “I want to make sure I did a good job explaining…”
  4. Tell Me: Encourage the participant to express their understanding in their own words. Be specific about what you expect them to relay back.
  5. Try Again: If the participant's understanding isn't clear, revisit the topic.

Reference: Anderson, Leister and DeRego, Health Literacy Research and Practice, 2020

Evaluating Understanding with Teach-Back

Training

E-Signature Instructions

The e-signature function in RSS is a way to electronically sign consent forms. It can be used if the consent process is conducted in person (face to face) or remotely (telephone or video as approved by the IRB). RSS e-signature can only be used for certain studies, outlined in the table below.

E-signature can only be used on newly created Narrative Consent Forms.

When can RSS e-signature be used? (as of 2/20/2024)

Study Types
FDA-regulated (drug/device) studies Yes
Non-FDA-regulated studies Yes
Commercially funded studies Yes
Federally funded studies Yes
CIRB (studies relying on an external IRB) No
Multi-site studies where UNMC is the IRB of record No

If you have any questions or would like to schedule a training session, please contact Sue Logsdon at slogsdon@unmc.edu.

Training

IRB Training Videos

Below are training topics related to the IRB, its history, and its function. Please let these videos serve as a training tool for those new to the IRB and research fields. If you need individual assistance with specific issues, or for general information, please contact us at irbora@unmc.edu or through the RSS Message Portal.

UNMC IRB Basics: Introduction to the Institutional Review Board

Getting Approved by the IRB: Everything You Need to Know

Ethical Access to Patients as Human Subjects of Research

IRB Considerations in Research Involving Drugs and Devices

Use of the IRB Short Form

Training

RSS Training

Guides to assist with RSS procedures:

If there is a topic that does not appear below, please contact irbora@unmc.edu

Adding Personnel

Adding Documents to an Application

Creating and navigating a New Application

Deleting Personnel

Functions within a Consent Form

How to submit an Incident Report

Navigating the RSS Dashboard

Signatures on a Consent Form

Submitting a Change Request

Using the in-person RSS E-Signature

Using the remote RSS E-Signature

Working within an Application 101

Training

Virtual Training/Office Hours

IRB Office Hours

We can be reached by phone (402-559-6463) or by email (irbora@unmc.edu) Mon-Fri 7am-5pm.

The IRB offers two virtual learning/training sessions each month.

Please direct questions regarding virtual training hours to the IRB Education Coordinator: Megan Berger mberger@unmc.edu or 402-559-6044

Forms

The following sections (located in the menu below will assist researchers by providing various tools and resources.

The IRB uses an electronic IRB submission system referred to as RSS. Never used the system before? Check the RSS Training section to learn more.

The IRB's Policy & Procedures Manual is available in UNMC Guides - https://guides.unmc.edu/books/hrpp-policies-and-procedures

Forms

Existing paper protocols

NOTE: THE PAPER FORMS ON THIS PAGE ARE ONLY TO BE USED FOR STUDIES THAT HAVE NOT BEEN TRANSFERRED TO THE ELECTRONIC SYSTEM (I.E. THEY ARE STILL IN PAPER FORMAT).

FORMS FOR EXISTING PAPER PROTOCOLS ONLY

Title Version Format
1. CR Biomedical Research 06/13/2022 Word
2. CR Social and Behavioral Research 06/13/2022 Word
3. CR Human Biological Materials 06/13/2022 Word
4. Study Completion Report 07/27/2010 Word
5. Request for Change in Protocol (Depending on the nature of the change completion of a protocol addendum may be required. Please contact the ORA for details.) 03/10/2014 Word
6. Request for Change* (Ads, Educational Items and Personnel Only) 05/14/2013 Word
7. Additional Personnel Change Form Pages (if more than four spaces needed) 08/17/2010 Word
8. P&T Drug Registry Form 04/14/2022 Word
Forms

FWAs - Federal Wide Assurance

The UNMC IRB Federal Wide Assurance documents can be found here:

Adult IRB Roster (FWA00002939)

Pediatric IRB Roster (FWA00002939)

Forms

Miscellaneous

Title Version Format
Investigator Assessment Checklist for Regulatory Documentation 9/17/2007 Word
Investigator Assessment of IRB 9/7/2007 Word
Forms

Recruitment templates

HRPP policy to review: #3.5 Subject Recruitment Through Advertisements

Recruitment Type Format
Flier - full page Word
Ad - one column Word
Ad - two column Word
Ad - six inch Word
Forms

Short Forms

A Short Form may be used when a subject/LAR who cannot understand English is unexpectedly encountered, there is not sufficient time to develop and obtain IRB approval for a complete ICF written in language understandable to the subject/LAR, AND the research presents the prospect of direct therapeutic benefit to the subject.

Use of the Short Form is limited to enrollment of no more than three subjects per language in a given protocol. In order to enroll more than three subjects, the PI is required to have the complete ICF translated into the appropriate language and reviewed and approved by the IRB.

The investigator must complete a Short Form Request (available in RSS) for each subject, and submit to the ORA. Each request must be approved before the Short Form may be used.

Depending on the nature and duration of the research, the IRB may determine that the English version of the complete ICF must be translated into a language understandable to the subject and a copy given to the subject as soon as possible after enrollment. In general, this may be required for studies which are significant risk and of long duration.

Please refer to HRPP Policy 5.5 (Use of the Short Form Consent Document) for detailed instructions.

English translations of these short forms is included at the bottom of the page. Translated Short Forms generously supplied by Office of Human Subjects Research - Johns Hopkins Medicine and the University of Utah. (Key: * - Johns Hopkins University; # - The University of Utah)

Short Forms

Albanian Short Form *

Arabic Short Form *

Bulgarian Short Form *

Burmese Short Form *

Cantonese Short Form *

Chinese Short Form *

English Translation *

Farsi Short Form *

French Short Form *

Greek Short Form *

Gujarati Short Form *

Haitian Creole Short Form *

Hebrew Short Form *

Hindi Short Form *

Hmong Short Form *

Hungarian Short Form *

Italian Short Form *

Japanese Short Form *

Karen Short Form (LLS)

Korean Short Form *

Lao Short Form *

Luganda Short Form *

Mandarin Short Form *

Nepali Short Form *

Polish Short Form *

Portuguese Short Form *

Romanian Short Form *

Russian Short Form *

Swahili Short Form *

Spanish Short Form *

Thai Short Form *

Ukranian Short Form *

Urdu Short Form *

Vietnamese Short Form *

Translated Short Forms generously supplied by Office of Human Subjects Research - Johns Hopkins Medicine and the University of Utah. (Key: * - Johns Hopkins University)

Forms

Subject's rights & responsibilities

Research Questions:

Amheric - Research Questions & Rights and Responsibilities

English (UNMC)

English (UNO)

Spanish (UNMC)

Spanish (UNO)

Rights of Research Subjects:

English

English (CHMC)

French

Somali

Spanish

Rights and What to know:

French

Karen

Interpretation Certificates:

Certificate 1

Certificate 2

Single & Central IRB

For applications with due dates on or after January 25, 2018, and contract solicitations published on or after January 25, 2018, NIH expects that all sites participating in multi-site studies, which involve non-exempt human subjects research funded by the NIH, will use a single Institutional Review Board (sIRB) to conduct the ethical review required for the protection of human subjects.

This policy applies to the domestic sites of NIH-funded multi-site studies where each site will conduct the same protocol involving non-exempt human subjects research. It does not apply to career development, research training or fellowship awards. Implementation of the NIH sIRB policy is expected to reduce unnecessary administrative burdens and systemic inefficiencies while maintaining appropriate human subjects protections.
_________________________________________________________________________________________________________
The UNMC single IRB (sIRB) team serves as resource for UNMC and external site study teams collaborating on multi-site projects.

Our mission is to provide high quality, timely IRB review for multi-site Human Subject Research.

Please speak with an sIRB analyst prior to submitting an sIRB request. Any questions regarding applications, fee schedules, consultations, and more please contact the sIRB team by email (sirb@unmc.edu).
_________________________________________________________________________________________________________
For multi-center studies, the central IRB is the IRB that conducts reviews on behalf of all study sites that agree to participate in the centralized review process. For sites at institutions that have an IRB that would ordinarily review research conducted at the site, the central IRB should reach agreement with the individual institutions participating in centralized review and those institutions' IRBs about how to apportion the review responsibilities between local IRBs and the central IRB (21 CFR 56.114).

Single & Central IRB

Glossary

Cede Review

An institution agrees to transfer IRB review and oversight authority for specified research to another institution’s IRB (reviewing IRB).

cIRB

<<<< insert definition >>>

Lead Site

<<<< insert definition >>>

Lead Principal Investigator (Lead Site PI)

The study wide lead Principal Investigator with ultimate responsibility for the conduct and integrity of multisite research.

Local Context
Participating Site (pSite)

<<<< insert definition >>>

Participating Site Principal Investigator (pSite PI)

The lead investigator at each institution participating in multisite research usually responsible for the conduct of the research at the participating institution.

Reliance

<<<< insert definition >>>

Reliance Agreement (also known as an Authorization Agreement)

An agreement between two Organizations engaged in human subject research that documents respective authorities, roles, responsibilities, and communication between the reviewing and relying IRBs.

Reliance Negotiation

<<<< insert definition >>>

Relying Institution

A participating Institution that cedes IRB review to the IRB of record (reviewing IRB) designated under a Reliance Agreement.

Relying IRB

<<<< insert definition >>>

Reviewing IRB

The IRB which is responsible for conducting IRB review and approval as described in 45 CFR 46.109 for cooperative human subject research.

sIRB

<<<< insert definition >>>

Single & Central IRB

sIRB - What is Single IRB?

Single IRB is a model of IRB review that is intended to streamline and reduce administrative burden on IRBs reviewing multisite studies. In a single IRB model, one IRB serves as the reviewing IRB or “IRB of Record” and the participating site (pSite) IRBs serve as relying IRBs. The responsibilities of each IRB are outlined in a document called a reliance agreement.

For more information on the history of single IRB (sIRB) review and sIRB review at UNMC, see each section below:

Single Site Research:

Below is a model of single site research, or research that is only taking place at one site.

single_site_research.png

Multi-site Research:

Historically, multisite research was overseen by multiple independent IRBs. This often led to differences in IRB review and outcomes across sites.

Below is a model of historical multisite research, or research that took place at more than one site.

multi_site_research.png

Single IRB Review Requirement:

The requirement for single IRB review originated from the NIH single IRB policy and the Revised Common Rule.

From the NIH:

"expectation that all [domestic] sites participating in multi-site studies involving non-exempt human subjects research funded by the National Institutes of Health will use a single Institutional Review Board (sIRB)" (NOT-OD-16-094, June 2016)

For more information on the NIH Single IRB Policy visit: https://grants.nih.gov/policy/humansubjects/single-irb-policy-multi-site-research.htm.

For Guidance on exceptions to the NIH Single IRB Policy, visit: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-003.html

From the Revised Common Rule:

"Any institution located in the United States that is engaged in cooperative research must rely upon approval by a single IRB …" (§_.114(b)(1))

For more information on the Revised Common Rule's Single IRB Requirement, visit: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46#46.114.

For a list of Common Rule Departments and Agencies, visit: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html

For information on Common Rule Exception Determinations, visit: https://www.hhs.gov/ohrp/regulations-and-policy/single-irb-requirement/index.html#exceptions

In short, this means that studies that are federally funded and taking place at more than one site are now required to use a single IRB as the IRB of record. There are many circumstances where it is not clear if a specific study requires single IRB review or if an exception may apply. In these cases, please email sirb@unmc.edu for assistance at the earliest opportunity.

Note: Participating site IRBs are still involved in the single IRB process and have their own local requirements, but the responsibility for the regulatory component of review is ceded to the single IRB. Each IRB’s responsibilities are outlined in a document called a Reliance Agreement. More information on reliance can be found in the sIRB Reliance section below.

Single IRB Review Models:

Some groups were already utilizing a single IRB model prior to the requirement (e.g., commercial IRBs).

Below is a simplified model of how some commercial IRBs handle multisite research. Many will interact directly with the sponsor, perform IRB review activities, and then push approvals to all sites simultaneously.

commercial_irb_1.png

Below is another model of how a single IRB may handle multisite research. In this example, the sponsor works with each site PI and study team independently. Each site submits their own application to the single IRB for review and receives separate approvals.

commercial_irb_1.png

sIRB Review at UNMC:

Single IRB Review at UNMC is broken out into two main parts. First, the overall study and lead site-specific requirements are reviewed. After overall study and lead site approval, participating sites (pSites) are onboarded and approved on a rolling basis.

sirb_review_unmc.png

Note: pSite IRB processes are not included in the above models. Please contact your pSite IRB directly with questions.

Single & Central IRB

sIRB - UNMC process

The UNMC sIRB Process is captured in the diagram below.

sirb_process.png

Contact sirb@unmc.edu with any UNMC sIRB process questions.

Single & Central IRB

sIRB - Submission deadlines

sIRB Submission Deadlines for New Submissions, Previously Tabled Protocols and Requests for Change

sIRB Full Board Submission Deadline – 9 am

Submission Deadline Date of sIRB Meeting
08/01/2024 08/09/2024
09/05/2024 09/13/2024
10/03/2024 10/11/2024
10/31/2024 11/08/2024
12/05/2024 12/13/2024
01/02/2025 01/10/2025
Single & Central IRB

sIRB - Reliance

Reliance refers to an arrangement where an IRB allows another IRB to perform review and approval of a study.

The UNMC IRB uses the term “single IRB” or “sIRB” to indicate that UNMC is serving as the reviewing IRB (i.e., the IRB of record) of a multisite study.

Reliance Agreement

A reliance agreement is a formal, written document that provides a mechanism for an institution engaged in research to delegate IRB review to another IRB. This document generally outlines the responsibility of the single IRB and the participating site. Often the reliance agreement is accompanied by addenda or other forms that are designed to further clarify responsibilities or collect pSite local context information.

Reliance agreements come in many formats. They may also be called:

UNMC's Preferred Reliance Agreement Format

UNMC is a SMART IRB participating site and strongly prefers to document reliance using the SMART IRB Online Reliance System (SMART IRB ORS). In addition, we ask that sites complete the SMART IRB Implementation Checklist. This will be provided during the reliance negotiation.

Note: SMART IRB is not an IRB, but a tool that IRBs use to document reliance.

Note: The UNMC sIRB Team has elected to initiate and maintain requests in the SMART IRB ORS, rather than have the lead site investigator or study team create requests. Please contact sirb@unmc.edu with questions.

If a site is not a SMART IRB participating institution, other reliance formats will be made available for use during the reliance negotiation.

Reliance Negotiation

The term reliance negotiation refers to the process of the reviewing and relying IRB representatives communicating and agreeing to the reliance agreement format and terms. The UNMC sIRB Team will initiate the negotiation during the pSite Onboarding stage of review.

Single & Central IRB

sIRB - Fees

For information regarding the fee schedule for Single IRB studies, please contact sirb@unmc.edu.

Single & Central IRB

cIRB - What is Central IRB?

The UNMC IRB uses the term “central IRB” or “cIRB” to indicate that the reviewing IRB (i.e., the IRB of record) of a multisite study is external to UNMC.

The UNMC IRB has contracted with two commercial IRBs, Advarra and WCG. In addition, the UNMC IRB partners with consortium, academic, and medical center IRBs nationwide.

For more details around the use of a cIRB, including when the use of an external central IRB is not permitted, see UNMC HRPP Policy 1.4 (UNMC Ceding Review to an External Central IRB).

Single & Central IRB

cIRB - UNMC Process

Note: When requesting cIRB review, study teams must satisfy the requirements of each IRB and the funding agency or sponsor (as applicable), prior to initiating the research.

UNMC cIRB Initial Review Process

cirb_review_process.png

External cIRB Process

Funding Agency/ Sponsor Process

Post-acceptance Study Activities

In general, the external IRB of record will be responsible for reviewing most study activities. In some cases, these may also need to be submitted to the UNMC IRB.

Things to submit to the external cIRB:

Note: In most cases, submit to the external IRB. If determined to be necessary, the external cIRB will notify the UNMC IRB directly or request the study team notify the UNMC IRB.

Things to submit to the UNMC IRB:

Note: personnel are NOT permitted to work on a study until UNMC IRB approval is received.

Note: Send a notification in the message portal, indicating the study is now closed. Upload applicable documentation.

Single & Central IRB

cIRB - Reliance

When requesting to rely on an external IRB, the UNMC IRB will assess the external IRB’s qualifications in accordance with HRPP Policy 1.4 (UNMC Ceding Review to an External Central IRB). The UNMC IRB may request information related, but not limited, to:

The UNMC IRB strongly prefers to document reliance using the SMART IRB Online Reliance System. UNMC has several reliance templates based on institution type available for use. Other reliance formats are approved on a case-by-case basis.

SMARTirb Logo

Single & Central IRB

cIRB - Fees

In line with most other academic medical centers and universities, the Office of Regulatory Affairs and the IRB charges an initial submission and an annual continuing review fee for commercial and industry sponsored protocols.

Central IRB:

effective 7/1/2021 Initial Submission Annual Continuing Reviews
Central IRB Review $3000 N/A

Single IRB:

Please contact sirb@unmc.edu for more information.
Single & Central IRB

cIRB - Forms & Links

Note: the UNMC IRB cannot answer questions related to external IRB processes or applications. Contact the external IRB's helpdesk or designated representative directly for assistance.

For questions regarding UNMC cIRB processes or applications, please contact sirb@unmc.edu.

Advarra

Advarra has requested the UNMC IRB number be added to the application as follows:

single_study_example_1.png

single_study_example_2.png

Contact Information Sheet

The UNMC IRB recognizes that not all central IRB consent templates have the option to add local study contacts. The cIRB application in RSS now has the option to build a “Contact Information Sheet” to be provided to subjects along with the approved consent documents.

***Older studies within RSS may not have this functionality. The Contact Information Sheet Template may be downloaded for manual completion.

Miscellaneous central IRBs

NCI CIRB

NMDP

SMART IRB

WCG

If requesting revisions to the template consent language, the University of Nebraska – WCG ICF Checklist must be completed and signed by the study’s lead UNMC IRB representative.

SROC

In accordance with all Federal Guidelines, the University of Nebraska and Board of Regents policy, the Scientific Research Oversight Committee (SROC) must review and approve all research using hESC lines and ONLY lines from the NIH Human Embryonic Stem Cell Registry (http://grants.nih.gov/stem_cells/registry/current.htm?sort=rnd) are allowed. Cell lines which are not on this registry are not allowed to be used for NU System research. The NIH Registration Number for a proposed stem cell line must be cited on your application for hESC use when submitting your application to the SROC.

The committee must be composed of scientists who have hESC expertise and at least 2 non-affiliated members, one of which must be a non-scientist.

Human embryonic stem cell research at UNMC: 

Current and prior protocols address a wide range of topics from the very basic mechanisms that regulate stem cell self renewal, which is the primary characteristic that distinguishes stem cells from all other cell types in the body, to potential applications of stem cells in regenerative medicine.

Studies have demonstrated the derivation of human hepatocytes (liver cells) from hES cells, retinal and neuronal (eye and brain) cells and shown that stem cells that are differentiated to fibroblasts of the lung in conditions similar to those in patients with asthma, are much more contractile than normally derived lung fibroblasts. This has prompted a new hypothesis to explain the persistence of asthma even in the face of anti-inflammatory treatments. Additional projects address the education aspects of the properties of hES cells. These results have been published in nationally ranked and recognized medical journals.

All studies must be SROC and IRB approved and employ federally approved hES cell lines that are used according to all federal, state and university regulations.

SROC

Chairs and Administrator

ahmad.jpg

Iqbal Ahmad, PhD

logsdon-sue.jpg

SROC

Committee

In 2008, the Human Embryonic Stem Cell Research Advisory Committee of the National Research Council and Institute of Medicine published Amendments to the National Academies’ Guidelines for Human Embryonic Stem Cell Research.

Section 2.0 (page 11) describes the establishment of an Institutional ESCRO “To provide oversight of all issues related to derivation and use of hES (human embryonic stem) cell lines and to facilitate education of investigators involved in hES cell research, each institution should have activities involving hES cells overseen by an Embryonic Stem Cell Research Committee (ESCRO).”

“An ESCRO committee should include independent representatives of the lay public as well as persons with expertise in developmental biology, stem cell research, molecular biology, assisted reproduction and ethical and legal issues in hES cell research.” (Since in Nebraska, development of human stem cell lines is not permitted, assisted reproduction input is potentially less relevant than in states that do not have this prohibition.)

“It must have suitable scientific, medical and ethical expertise to conduct its own review and should have the resources needed to coordinate the management of various other reviews required for a particular protocol.” (eg animal use, recombinant DNA, human subject research)

“But the ESCRO committee should not be a subcommittee of the IRB, as its responsibilities extend beyond human subject research.” (For example, in Nebraska, this includes ensuring that all hES cell lines employed are federally approved).

“The ESCRO Committee should

  1. Provide oversight over all issues related to deviation and use of hES cell lines.
  2. Review and approve the scientific merit of research protocols.
  3. Review compliance of all in-house hES cell research with all relevant regulations and these guidelines.
  4. Maintain registries of hES cell research conducted at the institution and hES cell lines derived (not relevant in Nebraska) or imported by institutional investigators.
  5. Facilitate education of investigators involved in hES cell research.”

The UNMC Scientific Research Oversight Committee (SROC) undertakes all of these tasks and reports its actions to the UNMC IRB and the Chancellor.

SROC

Forms

IRB Staff

This section will detail contact information for both IRB Staff and IRB Chairs.

IRB Staff

IRB Analysts/Staff

Deron Anderson, MS
IRB Analyst
402-559-5845
Email
Megan Berger, BS, MEd
IRB Analyst & Education Coordinator
402-559-6044
Email
Erika Boohar, BA
IRB Analyst
402-559-3853
Email
Bobbi Chapman, MS
IRB Analyst
402-559-6119
Email
Kristi DeHaai, MS, CIP
IRB Analyst
402-559-9991
Email
Emily Gale, BS
IRB Analyst
402-559-7269
Email
Bruce Gordon, MD Biography
Assistant Vice Chancellor for Regulatory Affairs
Executive Chair, Institutional Review Boards
Professor, Division of Pediatric Hematology/Oncology
402-559-6463
Email
Gail D. Kotulak, BS, CIP
IRB Analyst
402-559-6540
Email
Sue M. Logsdon, MS, CIP
IRB Analyst
402-559-3779
Email
Bryan Ludwig, BA, CIP
IRB Analyst
402-559-8561
Email
Jessica Odvody-Wernimont, BS
IRB Analyst
402-559-4741
Email
Nancy Olson, JD
IRB Analyst
601-946-9020
Email
Karli Storm-Narvainen, PhD
IRB Analyst
402-559-6898
Email
Nicole Weber, BA
IRB Analyst
402-559-6596
Email
IRB Staff

IRB Chairs

The Institutional Review Board (IRB) is composed of members from a variety of scientific disciplines and individuals from the community who assist investigators in the protection of the rights and welfare of human subjects.

Executive Chair

gordon-b.jpg

Bruce Gordon, MD

Executive Chair, UNMC Institutional Review Board

Chair, Joint Pediatric Institutional Review Board

402-559-6463

Email

Biography

Chairs

beam200.png

Elizabeth Beam, PhD, RN

Vice Chair, IRB-01 | Vice Chair, IRB-05

UNMC Institutional Review Board

402-559-6547

Email

lunning 125.jpg

Matthew Lunning, DO

Vice Chair, IRB-01 | Vice Chair, IRB-05

UNMC Institutional Review Board

402-559-7164

Email

AMacfadyen 125.jpg

Andrew Macfadyen, MD

Vice Chair, Children's Nebraska Joint Institutional Review Board

UNMC Institutional Review Board

402-955-4235

Email

sue_nuss 125.jpg

Suzanne Nuss, RN, MBA, PhD

Vice Chair, IRB-03 | Chair, IRB-05

UNMC Institutional Review Board

402-559-8815

Email

snyder 125.jpg

Sheilah Snyder, MD

Chair, Children's Nebraska Joint Institutional Review Board

UNMC Institutional Review Board

402-955-8125

Email

stoller 125.jpg

Douglas A. Stoller, MD, PhD

Vice Chair, IRB-01

UNMC Institutional Review Board

402-559-1350

Email

ben_teply 125.png

Benjamin Teply, MD

Vice Chair, IRB-02

UNMC Institutional Review Board

402-559-7915

Email

vaughn-b.jpg

Brigette Vaughan, APRN

Chair, IRB-02

UNMC/Children's Nebraska Joint Institutional Review Board

402-559-9800

Email

zeger-w.jpg

Wes Zeger, DO

Vice Chair, IRB-03

UNMC Institutional Review Board

402-559-6841

Email